Expansion of Interleukin‐22– and Granulocyte–Macrophage Colony‐Stimulating Factor–Expressing, but Not Interleukin‐17A–Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients With Spondyloarthritis

OBJECTIVE: Clinical trials of the anti–interleukin‐17A (anti–IL‐17A) antibody secukinumab have demonstrated a crucial role of the cytokine IL‐17A in the pathogenesis of spondyloarthritis (SpA); however, its cellular source in this condition remains a matter of controversy. Group 3 innate lymphoid ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Blijdorp, Iris C. J., Menegatti, Silvia, van Mens, Leonike J. J., van de Sande, Marleen G. H., Chen, Sijia, Hreggvidsdottir, Hulda S., Noordenbos, Troy, Latuhihin, Talia E., Bernink, Jochem H., Spits, Hergen, Rogge, Lars, Baeten, Dominique L. P., Yeremenko, Nataliya G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519165/
https://www.ncbi.nlm.nih.gov/pubmed/30260078
http://dx.doi.org/10.1002/art.40736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519165/
https://www.ncbi.nlm.nih.gov/pubmed/30260078
http://dx.doi.org/10.1002/art.40736

Ejemplares similares